Prevalence and outcome of bloodstream infections due to third-generation cephalosporin-resistant Enterobacteriaceae in sub-Saharan Africa: a systematic review.
Journal
The Journal of antimicrobial chemotherapy
ISSN: 1460-2091
Titre abrégé: J Antimicrob Chemother
Pays: England
ID NLM: 7513617
Informations de publication
Date de publication:
01 03 2020
01 03 2020
Historique:
received:
24
07
2019
revised:
06
10
2019
accepted:
10
10
2019
pubmed:
20
11
2019
medline:
25
6
2021
entrez:
20
11
2019
Statut:
ppublish
Résumé
The prevalence of bacterial bloodstream infections (BSIs) in sub-Saharan Africa (sSA) is high and antimicrobial resistance is likely to increase mortality from these infections. Third-generation cephalosporin-resistant (3GC-R) Enterobacteriaceae are of particular concern, given the widespread reliance on ceftriaxone for management of sepsis in Africa. Reviewing studies from sSA, we aimed to describe the prevalence of 3GC resistance in Escherichia coli, Klebsiella and Salmonella BSIs and the in-hospital mortality from 3GC-R BSIs. We systematically reviewed studies reporting 3GC susceptibility testing of E. coli, Klebsiella and Salmonella BSI. We searched PubMed and Scopus from January 1990 to September 2019 for primary data reporting 3GC susceptibility testing of Enterobacteriaceae associated with BSI in sSA and studies reporting mortality from 3GC-R BSI. 3GC-R was defined as phenotypic resistance to ceftriaxone, cefotaxime or ceftazidime. Outcomes were reported as median prevalence of 3GC resistance for each pathogen. We identified 40 articles, including 7 reporting mortality. Median prevalence of 3GC resistance in E. coli was 18.4% (IQR 10.5 to 35.2) from 20 studies and in Klebsiella spp. was 54.4% (IQR 24.3 to 81.2) from 28 studies. Amongst non-typhoidal salmonellae, 3GC resistance was 1.9% (IQR 0 to 6.1) from 12 studies. A pooled mortality estimate was prohibited by heterogeneity. Levels of 3GC resistance amongst bloodstream Enterobacteriaceae in sSA are high, yet the mortality burden is unknown. The lack of clinical outcome data from drug-resistant infections in Africa represents a major knowledge gap and future work must link laboratory surveillance to clinical data.
Sections du résumé
BACKGROUND
The prevalence of bacterial bloodstream infections (BSIs) in sub-Saharan Africa (sSA) is high and antimicrobial resistance is likely to increase mortality from these infections. Third-generation cephalosporin-resistant (3GC-R) Enterobacteriaceae are of particular concern, given the widespread reliance on ceftriaxone for management of sepsis in Africa.
OBJECTIVES
Reviewing studies from sSA, we aimed to describe the prevalence of 3GC resistance in Escherichia coli, Klebsiella and Salmonella BSIs and the in-hospital mortality from 3GC-R BSIs.
METHODS
We systematically reviewed studies reporting 3GC susceptibility testing of E. coli, Klebsiella and Salmonella BSI. We searched PubMed and Scopus from January 1990 to September 2019 for primary data reporting 3GC susceptibility testing of Enterobacteriaceae associated with BSI in sSA and studies reporting mortality from 3GC-R BSI. 3GC-R was defined as phenotypic resistance to ceftriaxone, cefotaxime or ceftazidime. Outcomes were reported as median prevalence of 3GC resistance for each pathogen.
RESULTS
We identified 40 articles, including 7 reporting mortality. Median prevalence of 3GC resistance in E. coli was 18.4% (IQR 10.5 to 35.2) from 20 studies and in Klebsiella spp. was 54.4% (IQR 24.3 to 81.2) from 28 studies. Amongst non-typhoidal salmonellae, 3GC resistance was 1.9% (IQR 0 to 6.1) from 12 studies. A pooled mortality estimate was prohibited by heterogeneity.
CONCLUSIONS
Levels of 3GC resistance amongst bloodstream Enterobacteriaceae in sSA are high, yet the mortality burden is unknown. The lack of clinical outcome data from drug-resistant infections in Africa represents a major knowledge gap and future work must link laboratory surveillance to clinical data.
Identifiants
pubmed: 31742611
pii: 5632029
doi: 10.1093/jac/dkz464
pmc: PMC7021093
doi:
Substances chimiques
Anti-Bacterial Agents
0
Cephalosporins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
492-507Subventions
Organisme : Wellcome Trust
ID : 203919/Z/16/Z
Pays : United Kingdom
Informations de copyright
© The Author(s) 2019. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy.
Références
Springerplus. 2015 Jul 03;4:314
pubmed: 26155453
Int J Med Microbiol. 2018 Oct;308(7):803-811
pubmed: 29980372
S Afr Med J. 2007 Apr;97(4):273-9
pubmed: 17446952
Antimicrob Agents Chemother. 2015;59(6):3133-9
pubmed: 25779570
PLoS One. 2015 Dec 23;10(12):e0145632
pubmed: 26700032
J Public Health (Oxf). 2017 Mar 1;39(1):8-13
pubmed: 26944074
Int J Antimicrob Agents. 2006 Sep;28(3):166-71
pubmed: 16904874
Clin Infect Dis. 2015 Nov 1;61 Suppl 4:S310-6
pubmed: 26449946
Arch Intern Med. 2002 Jan 28;162(2):185-90
pubmed: 11802752
Paediatr Int Child Health. 2015 Aug;35(3):265-72
pubmed: 25940506
Lancet Infect Dis. 2017 Oct;17(10):1042-1052
pubmed: 28818544
Clin Infect Dis. 2015 Nov 1;61 Suppl 4:S346-53
pubmed: 26449951
Lancet. 2016 Jan 16;387(10015):296-307
pubmed: 26603920
Afr J Infect Dis. 2016 May 01;10(2):89-95
pubmed: 28480442
Clin Infect Dis. 2006 Jan 15;42 Suppl 2:S82-9
pubmed: 16355321
PLoS One. 2015 Dec 15;10(12):e0144944
pubmed: 26670718
BMC Infect Dis. 2013 Feb 18;13:89
pubmed: 23419199
S Afr Med J. 2018 Feb 01;108(2):99-104
pubmed: 29429440
J Paediatr Child Health. 2011 Jan;47(1-2):5-11
pubmed: 20973858
Infect Drug Resist. 2015 May 11;8:99-106
pubmed: 25999745
BMC Pediatr. 2015 Apr 02;15:33
pubmed: 25884449
J Infect Dev Ctries. 2010 Jun 30;4(6):393-6
pubmed: 20601792
mBio. 2018 Feb 20;9(1):
pubmed: 29463654
Lancet. 2016 Oct 8;388(10053):1603-1658
pubmed: 27733283
BMC Infect Dis. 2017 Dec 6;17(1):750
pubmed: 29207958
J Antimicrob Chemother. 2011 Feb;66(2):398-407
pubmed: 21106563
Am J Trop Med Hyg. 2013 Nov;89(5):960-964
pubmed: 24043693
Paediatr Int Child Health. 2014 May;34(2):108-14
pubmed: 24621234
Euro Surveill. 2016 Sep 1;21(35):
pubmed: 27608263
Ann Clin Microbiol Antimicrob. 2016 Aug 18;15(1):49
pubmed: 27539221
J Infect Dev Ctries. 2016 Oct 31;10(10):1059-1064
pubmed: 27801367
Lancet Infect Dis. 2018 Feb;18(2):e33-e44
pubmed: 29033034
BMC Microbiol. 2006 Dec 15;6:101
pubmed: 17173674
J Antimicrob Chemother. 2005 Jul;56(1):232-5
pubmed: 15905304
S Afr Med J. 2014 Jun 19;104(8):563-8
pubmed: 25213849
PLoS One. 2008 Sep 24;3(9):e3260
pubmed: 18813340
J Antimicrob Chemother. 2014 Sep;69(9):2337-53
pubmed: 24879668
S Afr Med J. 2015 Apr 08;105(5):370-4
pubmed: 26242671
PLoS Negl Trop Dis. 2013;7(3):e2103
pubmed: 23516651
PLoS One. 2016 Feb 11;11(2):e0143729
pubmed: 26867226
Lancet Infect Dis. 2010 Jun;10(6):417-32
pubmed: 20510282
Antimicrob Resist Infect Control. 2016 May 14;5:18
pubmed: 27186369
Clin Infect Dis. 2017 Oct 1;65(7):1229-1231
pubmed: 29136410
Lancet. 2016 Jan 9;387(10014):168-75
pubmed: 26603918
Emerg Infect Dis. 2002 Feb;8(2):160-6
pubmed: 11897067
BMC Infect Dis. 2016 Oct 17;16(1):570
pubmed: 27751185
BMJ Open. 2015 May 11;5(5):e007397
pubmed: 25967999
Lancet Infect Dis. 2018 Mar;18(3):318-327
pubmed: 29276051
BMC Infect Dis. 2014 Dec 21;14:3857
pubmed: 25528352
Clin Infect Dis. 2015 Nov 1;61 Suppl 4:S251-8
pubmed: 26449939
East Afr Med J. 2010 Feb;87(2):74-80
pubmed: 23057259
BMC Public Health. 2012 Oct 24;12:904
pubmed: 23095365
BMC Infect Dis. 2007 May 22;7:43
pubmed: 17519011
Int J Med Microbiol. 2016 Jun;306(4):249-54
pubmed: 27222489
Clin Infect Dis. 2015 Nov 1;61 Suppl 4:S363-71
pubmed: 26449953
BMC Infect Dis. 2016 Oct 20;16(1):587
pubmed: 27765017
BMC Res Notes. 2015 Jul 03;8:289
pubmed: 26138060
BMC Res Notes. 2009 Mar 26;2:49
pubmed: 19323805
PLoS One. 2014 Feb 14;9(2):e89103
pubmed: 24551225
BMC Med. 2019 Mar 29;17(1):70
pubmed: 30922309
Clin Infect Dis. 2019 Jun 18;69(1):61-68
pubmed: 30277505
Ann Intern Med. 2004 Jan 6;140(1):26-32
pubmed: 14706969